---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-014678"
form_type: "8-K"
ticker: "AGEN"
cik: "0001098972"
company_name: "AGENUS INC"
filed_at: "2026-01-16T23:59:59+00:00"
generated_at: "2026-05-16T09:42:54.149406+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Agenus closes $141M strategic collaboration with Zydus; sells manufacturing, issues equity, licenses BOT/BAL

## Summary
- Zydus pays $75M cash for Agenus' biologics manufacturing facilities in Emeryville and Berkeley, CA.
- Zydus affiliate purchases 2,133,333 AGEN shares at $7.50 ($16M) in concurrent equity investment.
- Agenus eligible for up to $50M in contingent payments based on BOT+BAL production orders over 36 months.
- Exclusive license to Zydus for BOT and BAL in India and Sri Lanka; Agenus receives 5% royalty on net sales.
- Pro forma shows estimated $37.5M gain on derecognition and net cash of ~$58.4M at closing.

## SEC filing metadata
- accession: 0001193125-26-014678
- form_type: 8-K
- ticker: AGEN
- cik: 0001098972
- company_name: AGENUS INC
- filed_at: 2026-01-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.01, 9.01, 3.02, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1098972/000119312526014678/0001193125-26-014678-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1098972/000119312526014678/agen-20260115.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-014678
- JSON: https://secwatch.observer/filing/0001193125-26-014678.json
- Plain text: https://secwatch.observer/filing/0001193125-26-014678.txt

## Source-grounded claims
- claim_id: c0bd0487370d1467fb43821670e939bb1940ce9b
  claim: AGENUS INC completed a disposition involving Zydus Pharmaceuticals (USA) Inc. (subsequently assigned to Zydilac Bio, LLC) for $75.0 million (closed 2026-01-15).
  evidence_excerpt: On January 15, 2026, the transactions contemplated by the Purchase Agreement closed. Pursuant to the Purchase Agreement, on January 15, 2026, Agenus received consideration of $75.0 million, less certain reimbursable expenses and other required closing payments. The disposition of the Purchased Assets constituted a significant business disposition for the purposes
  evidence_url: https://www.sec.gov/Archives/edgar/data/1098972/000119312526014678/0001193125-26-014678-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.